Brief Description
Lyterian Therapeutics is committed to developing transformative medicines for patients by co-opting physiologically relevant protein homeostatic mechanisms to regulate genetically-validated targets. Lyterian is derived from λυτήριος or lutḗrios, which means termination, healing, or end of disease. Disease resolution is coordinated by endogenous and exogenous agents that recruit cells and other effectors to the site of injury. Lyterian Therapeutics medicines are inspired by the logic that orchestrates homeostatic equilibria and drives healing.
Inventors
Michael Rape, Julia Sabine Schaletzky, Stephanie See, Edward Eric Wehri
Company Founders
Ingrid Wertz, Aaron Gitler, Marius Wernig, Michael Rape (UC Berkeley Professor of Cell and Developmental Biology), Robert Tjian (UC Berkeley, B.A., Biochemistry, 1971)
Timeline
- 2022. Company founded